A hexane fraction of guava leaves (Psidium guajava L.) induces anticancer activity by suppressing AKT/mammalian target of rapamycin/ribosomal p70 S6 kinase in human prostate cancer cells

Journal of Medicinal Food

Volumn 15, Issue 3, 2012, Pages 231-241

  Ryu, Nae Hyung ^a   Park, Kyung Ran ^a   Kim, Sung Moo ^a   Yun, Hyung Mun ^a   Nam, Dongwoo ^a   Lee, Seok Geun ^a   Jang, Hyeung Jin ^a   Ahn, Kyoo Seok ^a   Kim, Sung Hoon ^a   Shim, Bum Sang ^a   Choi, Seung Hoon ^a   Mosaddik, Ashik ^b   Cho, Somi K ^b   Ahn, Kwang Seok ^a  

^a Kyung Hee University   (South Korea)

^b Jeju National University   (South Korea)

Author keywords

AKT mammalian target of rapamycin ribosomal p70 S6 kinase; Apoptosis; Guava leaves; Prostate cancer

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALPHA PATCHOULENE; BETA EUDESMOL; CARYOPHYLLA 3(15),7(14) DIEN 6 OL; CARYOPHYLLENE OXIDE; CASPASE 3; COPAENE; GUAVA EXTRACT; HEXANE; MAMMALIAN TARGET OF RAPAMYCIN; METHYL ISOEUGENOL; MITOGEN ACTIVATED PROTEIN KINASE; OCTADECANE; PHYTOL; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RIBOSOMAL P70 S6 KINASE; SH 5; TERPENE DERIVATIVE; TERPINEOL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMICAL COMPOSITION; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; PLANT LEAF; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; DRUG DISCOVERY; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; NEOPLASM PROTEINS; PHOSPHORYLATION; PLANT EXTRACTS; PLANT LEAVES; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PSIDIUM; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SESQUITERPENES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

PSIDIUM; PSIDIUM GUAJAVA;

EID: 84863286137     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2011.1701     Document Type: Article

References (63)

1. Goncalves FA, Andrade Neto M, Bezerra JN, et al.: Antibacterial activity of guava, Psidium guajava Linnaeus, leaf extracts on diarrhea-causing enteric bacteria isolated from Seabob shrimp, Xiphopenaeus kroyeri (Heller). Rev Inst Med Trop Sao Paulo 2008;50:11-15. (Pubitemid 351416348)
2. Lozoya X, Reyes-Morales H, Chavez-Soto MA, Martinez-Garcia Mdel C, Soto-Gonzalez Y, Doubova SV: Intestinal anti-spasmodic effect of a phytodrug of Psidium guajava folia in the treatment of acute diarrheic disease. J Ethnopharmacol 2002;83:19-24. (Pubitemid 36164723)
3. Deguchi Y, Miyazaki K: Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract. Nutr Metab (Lond) 2010;7:9.
4. Qadan F, Thewaini AJ, Ali DA, Afifi R, Elkhawad A, Matalka KZ: The antimicrobial activities of Psidium guajava and Juglans regia leaf extracts to acne-developing organisms. Am J Chin Med 2005;33:197-204. (Pubitemid 40668095)
5. Steinhaus M, Sinuco D, Polster J, Osorio C, Schieberle P: Characterization of the key aroma compounds in pink guava (Psidium guajava L.) by means of aroma re-engineering experiments and omission tests. J Agric Food Chem 2009;57:2882-2888.
6. Jaiarj P, Khoohaswan P, Wongkrajang Y, et al.: Anticough and antimicrobial activities of Psidium guajava Linn. leaf extract. J Ethnopharmacol 1999;67:203-212. (Pubitemid 29421676)
7. Lutterodt GD, Maleque A: Effects on mice locomotor activity of a narcotic-like principle from Psidium guajava leaves. J Ethnopharmacol 1988;24:219-231. (Pubitemid 19022071)
8. Osman AM, Younes MG, Sheta AE: Triterpenoids of the leaves of Psidium guaijava. Phytochemistry 1974;13:2015-2016.
9. Prabu GR, Gnanamani A, Sadulla S: Guaijaverin-plant flavonoid as potential antiplaque agent against Streptococcus mutans. J Appl Microbiol 2006;101:487-495. (Pubitemid 44060431)
10. Li J, Chen F, Luo J: [GC-MS analysis of essential oil from the leaves of Psidium guajava]. Zhong Yao Cai 1999;22:78-80.
11. Tanaka T, Ishida N, Ishimatsu M, Nonaka G, Nishioka I: Tannins and related compounds. CXVI. Six new complex tannins, guajavins, psidinins and psiguavin from the bark of Psidium guajava L. Chem Pharm Bull 1992;40:2092-2098.
12. Choi SY, Hwang JH, Park SY, et al.: Fermented guava leaf extract inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells by inhibition of transcription factor NFkappaB. Phytother Res 2008;22:1030-1034.
13. Akinola OB, Oladosu OS, Dosumu OO: Spermatoprotective activity of the leaf extract of Psidium guajava Linn. Niger Postgrad Med J 2007;14:273-276.
14. Manosroi J, Dhumtanom P, Manosroi A: Anti-proliferative activity of essential oil extracted from Thai medicinal plants on KB and P388 cell lines. Cancer Lett 2006;235:114-120.
15. Chen KC, Hsieh CL, Huang KD, Ker YB, Chyau CC, Peng RY: Anticancer activity of rhamnoallosan against DU-145 cells is kinetically complementary to coexisting polyphenolics in Psidium guajava budding leaves. J Agric Food Chem 2009;57:6114-6122.
16. Chen KC, Peng CC, Chiu WT, et al.: Action mechanism and signal pathways of Psidium guajava L. aqueous extract in killing prostate cancer LNCaP cells. Nutr Cancer 2010;62:260-270.
17. Kawakami Y, Nakamura T, Hosokawa T, et al.: Antiproliferative activity of guava leaf extract via inhibition of prostaglandin endoperoxide H synthase isoforms. Prostaglandins Leukot Essent Fatty Acids 2009;80:239-245.
18. Hsieh CL, Huang CN, Lin YC, Peng RY: Molecular action mechanism against apoptosis by aqueous extract from guava budding leaves elucidated with human umbilical vein endothelial cell (HUVEC) model. J Agric Food Chem 2007;55:8523-8533. (Pubitemid 350017470)
19. Edwards J, Bartlett JM: The androgen receptor and signaltransduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 2005;95: 1320-1326. (Pubitemid 40799454)
20. Petrylak D: Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int 2005;96(Suppl 2):41-46. (Pubitemid 43041976)
21. Shaw GL, Wilson P, Cuzick J, et al.: International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 2007;99:1056-1065. (Pubitemid 46587917)
22. Martin GS: Cell signaling and cancer. Cancer Cell 2003;4:167-174. (Pubitemid 37163830)
23. Yang L, Xie S, Jamaluddin MS, et al.: Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem 2005;280:33558-33565. (Pubitemid 41397156)
24. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ: Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001;142:4795-4805. (Pubitemid 33022355)
25. Majumder PK, Febbo PG, Bikoff R, et al.: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601. (Pubitemid 38796850)
26. Hudson CC, Liu M, Chiang GG, et al.: Regulation of hypoxiainducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-7014.
27. van der Poel HG: Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells. J Urol 2004;172:1333-1337. (Pubitemid 39249709)
28. Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S: mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug Targets 2008;8:647-665.
29. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998;95:1432-1437. (Pubitemid 28103409)
30. Isotani S, Hara K, Tokunaga C, Inoue H, Avruch J, Yonezawa K: Immunopurified mammalian target of rapamycin phosphorylates and activates p70 S6 kinase alpha in vitro. J Biol Chem 1999;274:34493-34498. (Pubitemid 129511797)
31. Westphal RS, Coffee RL Jr, Marotta A, Pelech SL, Wadzinski BE: Identification of kinase-phosphatase signaling modules composed of p70 S6 kinase-protein phosphatase 2A (PP2A) and p21-activated kinase-PP2A. J Biol Chem 1999;274:687-692.
32. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL: Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 1995;377:441-446.
33. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ: p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001;98:9666-9670. (Pubitemid 32769360)
34. Gao N, Zhang Z, Jiang BH, Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 2003;310:1124-1132. (Pubitemid 37237653)
35. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-183. (Pubitemid 41317589)
36. Kondjoyan N, Berdague JL: A Compilation of Relative Retention Indices for the Analysis of Aromatic Compounds. Laboratoire Flaveur Ed., INRA, Clermont-Ferrand, France, 1996.
37. Acree TE, Ahn H: Flavornet. www.nysaes.cornell.edu/flavornet Geneva: Cornell University, 1997.
38. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-1136. (Pubitemid 27097313)
39. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336. (Pubitemid 120029101)
40. Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T: The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J Biol Chem 2000;275:26661-26664.
41. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-3257. (Pubitemid 34953189)
42. Earnshaw WC, Martins LM, Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999;68:383-424. (Pubitemid 29449198)
43. Slee EA, Harte MT, Kluck RM, et al.: Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol 1999;144:281-292. (Pubitemid 29066031)
44. van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schroder FH: The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 1991;40:207-214.
45. Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr: Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001;276:18934-18940.
46. Lee JY, Ye J, Gao Z, et al.: Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J Biol Chem 2003;278:37041-37051. (Pubitemid 37175218)
47. Ahn KS, Sethi G, Aggarwal BB: Nuclear factor-kappa B: from clone to clinic. Curr Mol Med 2007;7:619-637. (Pubitemid 350201663)
48. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN: The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2009;35:148-159.
49. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSCmTOR pathway in human disease. Nat Genet 2005;37:19-24. (Pubitemid 40070934)
50. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
51. Campone M, Levy V, Bourbouloux E, et al.: Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 2009;100: 315-321.
52. Qian Y, Corum L, Meng Q, et al.: PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration. Am J Physiol Cell Physiol 2004;286: C153-C163. (Pubitemid 38055824)
53. Qiu Q, Yang M, Tsang BK, Gruslin A: Both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signalling are required in epidermal growth factor-induced human trophoblast migration. Mol Hum Reprod 2004;10:677-684. (Pubitemid 39341589)
54. Berven LA, Willard FS, Crouch MF: Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 2004;296:183-195. (Pubitemid 38624640)
55. Wendel HG, De Stanchina E, Fridman JS, et al.: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-337. (Pubitemid 38418805)
56. Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-10985. (Pubitemid 32928669)
57. Pullen N, Thomas G: The modular phosphorylation and activation of p70s6k. FEBS Lett 1997;410:78-82.
58. Lebedeva IV, Sarkar D, Su ZZ, et al.: Bcl-2 and Bcl-xL differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/ IL-24. Oncogene 2003;22:8758-8773. (Pubitemid 38010500)
59. Zhang M, Latham DE, Delaney MA, Chakravarti A: Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005;24:2474-2482. (Pubitemid 40593038)
60. Ho CL, Wang EI, Tseng YH, et al.: Composition and antimicrobial activity of the leaf and twig oils of Litsea mushaensis and L. linii from Taiwan. Nat Prod Commun 2010;5:1823-1828.
61. Ali NA, Marongiu B, Piras A, et al.: Essential oil composition of leaves of Stachys yemenensis obtained by supercritical CO. Nat Prod Res 2010;24:1823-1829.
62. Jordan MJ, Margaria CA, Shaw PE, Goodner KL: Volatile components and aroma active compounds in aqueous essence and fresh pink guava fruit puree (Psidium guajava L.) by GC-MS and multidimensional GC/GC-O. J Agric Food Chem 2003;51: 1421-1426.
63. Paterson WG, Barkun AN, Hopman WM, et al.: Wait times for gastroenterology consultation in Canada: the patients' perspective. Can J Gastroenterol 2010;24:28-32.